J. Blatter
About
J. Blatter is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, J. Blatter has authored 66 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in J. Blatter's work include Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Treatment and Pharmacology (13 papers). J. Blatter is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Colorectal Cancer Treatments and Studies (13 papers) and Cancer Treatment and Pharmacology (13 papers). J. Blatter collaborates with scholars based in Germany, United States and United Kingdom. J. Blatter's co-authors include Giorgio V. Scagliotti, Patrick Peterson, Lorinda Simms, Katherine P. Sugarman, Frances A. Shepherd, Nasser H. Hanna, Frank V. Fossella, Christian Manegold, M.F. Spittle and Adrian L. Harris and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and CHEST Journal.
In The Last Decade
J. Blatter
66 papers receiving 2.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| J. Blatter Germany | 21 | 1.8k | 1.3k | 516 | 345 | 338 | 66 | 2.7k | ||
| Panos Fidias United States | 25 | 1.8k 1.0× | 1.7k 1.3× | 925 1.8× | 210 0.6× | 276 0.8× | 58 | 3.0k | ||
| Coleman K. Obasaju United States | 32 | 3.0k 1.6× | 2.3k 1.7× | 775 1.5× | 600 1.7× | 427 1.3× | 157 | 4.1k | ||
| Francisco Robert United States | 28 | 1.4k 0.7× | 1.8k 1.4× | 1.1k 2.2× | 231 0.7× | 312 0.9× | 107 | 3.2k | ||
| Vera Gorbounova Russia | 13 | 1.8k 1.0× | 2.2k 1.7× | 617 1.2× | 280 0.8× | 354 1.0× | 23 | 3.2k | ||
| Joo Hang Kim South Korea | 27 | 1.9k 1.0× | 1.9k 1.4× | 789 1.5× | 326 0.9× | 426 1.3× | 91 | 3.0k | ||
| C. Logothetis United States | 23 | 1.1k 0.6× | 817 0.6× | 690 1.3× | 1.0k 2.9× | 403 1.2× | 71 | 2.4k | ||
| Maria Carmela Piccirillo Italy | 26 | 787 0.4× | 1.2k 0.9× | 502 1.0× | 223 0.6× | 408 1.2× | 94 | 2.3k | ||
| G Dabouis France | 21 | 1.5k 0.8× | 1.5k 1.1× | 450 0.9× | 161 0.5× | 124 0.4× | 69 | 2.3k | ||
| Clet Niyikiza United States | 15 | 3.0k 1.6× | 1.4k 1.1× | 585 1.1× | 264 0.8× | 176 0.5× | 29 | 3.8k | ||
| Masao Harada Japan | 23 | 1.9k 1.0× | 1.8k 1.4× | 675 1.3× | 189 0.5× | 246 0.7× | 70 | 2.5k |
Countries citing papers authored by J. Blatter
Since
Specialization
Citations
This map shows the geographic impact of J. Blatter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Blatter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Blatter more than expected).
Fields of papers citing papers by J. Blatter
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. Blatter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Blatter. The network helps show where J. Blatter may publish in the future.
Co-authorship network of co-authors of J. Blatter
This figure shows the co-authorship network connecting the top 25 collaborators of J. Blatter. A scholar is included among the top collaborators of J. Blatter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Blatter. J. Blatter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Taylor, Paul, B. Castagneto, G. Dark, et al.. (2008). Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. Journal of Thoracic Oncology. 3(7). 764–771.
2.
Santoro, Armando, Mary O’Brien, Rolf A. Stahel, et al.. (2008). Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program. Journal of Thoracic Oncology. 3(7). 756–763.
3.
Santoro, Armando, Paolo Andrea Zucali, Mary O’Brien, et al.. (2007). Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP). Annals of Oncology. 18. 32–32.
4.
Manegold, Christian, Armando Santoro, Mary O’Brien, et al.. (2007). C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP). Journal of Thoracic Oncology. 2(8). S371–S371.
5.
Hanauske, Axel-Rainer, Ulrike Eismann, Olaf Oberschmidt, et al.. (2007). Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells. Investigational New Drugs. 26(3). 215–222.
6.
Underhill, Craig, David Goldstein, Vera Gorbounova, et al.. (2007). A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer. Oncology. 73(1-2). 9–20.
7.
Gatzemeier, U., Paul Taylor, Joachim von Pawel, et al.. (2007). C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP). Journal of Thoracic Oncology. 2(8). S372–S373.
8.
Adams, Clive E, John Rathbone, Judy Wright, et al.. (2007). Schizophrenia trials in China: a survey. Acta Psychiatrica Scandinavica. 116(1). 6–9.
9.
Perez‐Gracia, José Luis, María del Mar Muñoz, Grant Williams, et al.. (2005). Assessment of the value of confirming responses in clinical trials in oncology. European Journal of Cancer. 41(11). 1528–1532.
10.
Bauknecht, Thomas, G Morack, C Villena-Heinsen, et al.. (2003). Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. International Journal of Gynecological Cancer. 13(2). 130–137.
11.
Thödtmann, R., Thilo Sauter, S. Weinknecht, et al.. (2003). A phase II trial of pemetrexed in patients with metastatic renal cancer. Investigational New Drugs. 21(3). 353–358.
12.
Albers, Peter, Roswitha Siener, Michael Haertlein, et al.. (2002). Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life. Oncology Research and Treatment. 25(1). 47–52.
13.
Haberkorn, Uwe, Matthias E. Bellemann, Gunnar Brix, et al.. (2001). Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. European Journal of Nuclear Medicine and Molecular Imaging. 28(4). 418–425.
14.
Manegold, C., U. Gatzemeier, Joachim von Pawel, et al.. (2000). Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial. Annals of Oncology. 11(4). 435–440.
15.
Zatloukal, Petr, et al.. (2000). Gemcitabine in Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs. 18(1). 29–42.
16.
Kornmann, Marko, et al.. (2000). Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. European Journal of Surgical Oncology. 26(6). 583–587.
17.
Latz, D., Katharina Fleckenstein, Michael J. Eble, et al.. (1998). Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. International Journal of Radiation Oncology*Biology*Physics. 41(4). 875–882.
18.
Weißbach, L., et al.. (1996). Experimental and Clinical Efficacy of 2′,2′-Difluorodeoxycytidine (Gemcitabine) against Renal Cell Carcinoma. Oncology. 53(6). 476–481.
19.
Mulder, P.H.M. de, et al.. (1996). Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemotherapy and Pharmacology. 37(5). 491–495.
20.
Clorius, John H., Hannsjörg Sinn, J. Blatter, et al.. (1995). Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging. 22(9). 989–996.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Coleman K. Obasaju Breakdown of academic impact, for papers by Francisco Robert Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Joo Hang Kim Breakdown of academic impact, for papers by C. Logothetis Breakdown of academic impact, for papers by Maria Carmela Piccirillo Breakdown of academic impact, for papers by G Dabouis Breakdown of academic impact, for papers by Clet Niyikiza Breakdown of academic impact, for papers by Masao Harada